Tag Archives: Teva Pharma

Oppenheimer Remains a Hold on Teva Pharma (TEVA)

In a report released today, Esther Rajavelu from Oppenheimer maintained a Hold rating on Teva Pharma (TEVA – Research Report), with a price target of $21. The company’s shares opened today at $17.41. Rajavelu wrote: “We are updating our model

Teva Pharma (TEVA) Receives a Hold from Oppenheimer

Oppenheimer analyst Esther Rajavelu maintained a Hold rating on Teva Pharma (TEVA – Research Report) today and set a price target of $21. The company’s shares closed yesterday at $17.63. Rajavelu wrote: “TEVA reported 4Q18 results and provided full-year guidance

Teva Pharma (TEVA) Receives a Hold from Credit Suisse

In a report released yesterday, Vamil Divan from Credit Suisse maintained a Hold rating on Teva Pharma (TEVA – Research Report), with a price target of $26. The company’s shares closed yesterday at $19.96. According to TipRanks.com, Divan has currently

Teva Pharma (TEVA) Gets a Buy Rating from Merrill Lynch

Merrill Lynch analyst Jason Gerberry reiterated a Buy rating on Teva Pharma (TEVA – Research Report) today and set a price target of $24. The company’s shares closed yesterday at $19.67. According to TipRanks.com, Gerberry is ranked 0 out of

Oppenheimer Keeps Their Hold Rating on Teva Pharma (TEVA)

Oppenheimer analyst Esther Rajavelu maintained a Hold rating on Teva Pharma (TEVA – Research Report) today. The company’s shares closed yesterday at $23.09. Rajavelu commented: “With three CGRP-mabs on market, we spoke to a high-prescribing neurologist who works at a

Wells Fargo Maintains a Hold Rating on Teva Pharma (TEVA)

In a report released today, David Maris from Wells Fargo maintained a Hold rating on Teva Pharma (NYSE: TEVA). The company’s shares opened today at $22.86. According to TipRanks.com, Maris has currently no stars on a ranking scale of 0-5